How pharmacy reviews support funding decisions
Use clinical evidence to make informed medication funding choices in injury claims
Published: 3 April 2026 | Updated: 3 April 2026
The challenge of medication funding decisions
As a claims manager, you make decisions about which medications to fund. These decisions are not straightforward. You receive requests for expensive medications, alternative therapies, or extended treatment periods. You face pressure to balance claimant expectations, medical provider recommendations, cost control, and your obligation to provide appropriate care. Medication funding decisions can become contentious, with claimants, medical providers, and funders all advocating for different positions.
Pharmacy review provides the clinical foundation you need to make these decisions confidently. Rather than funding medications based on medical provider recommendations alone, or denying medications based on cost considerations, pharmacy review gives you independent clinical expertise to support evidence-based funding decisions that serve claimant interests while controlling costs.
Key insight: Medication funding decisions made with specialist pharmacy input are better supported, less likely to be challenged, and more likely to result in appropriate claimant outcomes. They reduce disputes while improving care quality.
Using pharmacy review to establish funding criteria
Rather than making ad-hoc funding decisions, use pharmacy review to establish consistent, evidence-based criteria for medication funding. This approach provides clarity to medical providers, claimants, and your own team about what medications you will fund and under what circumstances.
Pain medications
Funding decision framework
Acute phase (0-12 weeks): Fund all appropriate pain medications recommended by treating providers. Preference for non-opioid approaches when possible. Opioids appropriate for moderate-to-severe acute pain.
Subacute phase (12-26 weeks): Transition to non-opioid pain management preferred. Continue opioids only with documented evidence of benefit and clear plan for eventual reduction. Maximum dose and duration should be established.
Chronic phase (26+ weeks): Fund opioids only with specialist pain management input. Require documentation of: failed trials of alternative pain management, clear ongoing benefit, addiction risk assessment, and agreed reduction timeline. Deprescribing plan required for continued funding.
Antidepressants
Funding decision framework
Acute injury-related depression/anxiety: Fund first-line antidepressants for documented injury-related mood symptoms. Typical duration 12-24 months.
Beyond 24 months: Require documentation of ongoing depression/anxiety symptoms and clinical benefit. Fund only if medical evidence supports continued need. Specialist psychiatric input recommended.
Switching or escalating antidepressants: Require documented trial of current medication and clinical justification for change. Fund alternatives only with specialist mental health provider recommendation.
Deprescribing plans: Require timeline for gradual reduction once appropriate. Fund gradual tapering process, including medication visits or psychological support during withdrawal period.
Benzodiazepines
Funding decision framework
Acute use (0-12 weeks): Fund for severe acute anxiety or sleep disturbance in early injury phase. Require explicit reduction plan at time of prescribing. Fund only for diagnosed acute insomnia or anxiety, not for habitual sedation.
Beyond 12 weeks: Do not fund continued benzodiazepines. Only exception is tapered cessation with clear reduction schedule. Fund structured withdrawal management (medical visits, psychological support) if needed for safe cessation.
Alternative anxiety/sleep management: Fund evidence-based alternatives: cognitive behavioural therapy for insomnia, exercise, sleep hygiene support, anxiety counselling.
Key funding decision scenarios and pharmacy review's role
Scenario 1: Expensive new medication requested
Situation: Your claimant's psychiatrist requests funding for a new antidepressant at $200/month versus the current medication at $30/month.
Funding challenge: Is the new medication clinically indicated? Has the current medication been given adequate trial? Is the cost difference justified by clinical benefit?
Pharmacy review role: Specialist review can assess:
- Whether current medication has been at therapeutic dose for adequate duration
- Whether switching is evidence-based or preference-driven
- Whether the new medication offers clinical advantages justifying cost
- Whether cost-effective alternatives exist with similar efficacy
Funding decision: "Funding for the new medication is approved conditional on documentation that the current medication has been at therapeutic dose for 12 weeks and that clinical benefit has plateaued. Pharmacy review confirms clinical appropriateness of the switch."
Scenario 2: Medication cost escalating without functional improvement
Situation: Your claimant's pharmacy costs have doubled over 12 months. Medication count increased from four to seven medications. Functional capacity has not improved.
Funding challenge: Should you continue funding all medications? Are they all necessary? Should you cap medication spending?
Pharmacy review role: Comprehensive review can assess:
- Necessity of each medication and clinical indication
- Whether medications are supporting functional recovery
- Whether side effects are limiting recovery
- Opportunities to reduce from seven to three or four essential medications
- Cost savings achievable through medication simplification
Funding decision: "Continued funding of all medications is not approved. Pharmacy review identifies opportunities to reduce to four essential medications while maintaining clinical benefit. Fund implementation of pharmacy recommendations. Follow-up review in 8 weeks."
Scenario 3: Deprescribing versus ongoing cost
Situation: Your claimant has been on sedating medications for two years. Functional recovery has plateaued. Medical provider suggests continuing indefinitely. You face either ongoing medication costs or deprescribing with potential withdrawal effects.
Funding challenge: What is the evidence for continued medication use? Should you fund deprescribing and associated support, even though it creates short-term risk?
Pharmacy review role: Specialist assessment can determine:
- Whether continuing sedating medications is evidence-based
- Whether deprescribing offers better long-term outcome potential
- What support (counselling, medical monitoring) is needed for safe deprescribing
- Timeline and probability of successful deprescribing
Funding decision: "Funding for continued sedating medications without deprescribing plan is not approved. Funding is approved for pharmacy-guided deprescribing plan including medical support, psychological support, and close monitoring. Deprescribing support is covered as essential to functional recovery."
Scenario 4: Medication versus alternative treatment
Situation: Your claimant's psychiatrist recommends ongoing medication for depression. Clinical psychologist recommends cognitive behavioural therapy (CBT) as an alternative or complement. Cost of medication is $50/month, cost of CBT is $150 per session weekly.
Funding challenge: Should you fund medication, therapy, or both? Which offers better evidence-based outcome?
Pharmacy review role: Can assess:
- Whether medication dose and type are optimised
- Whether medication plus psychological therapy offers better outcomes than medication alone
- Timeline for potential medication reduction if therapy is successful
- Cost-effectiveness of combined approach versus medication alone
Funding decision: "Funding approved for both antidepressant medication and structured CBT. Evidence supports combined approach for better outcomes. Antidepressant therapy anticipated to be reduced once CBT demonstrates benefit."
Pharmacy review evidence to support funding decisions
When requesting pharmacy review to support medication funding decisions, provide these details to guide the assessment:
- Clinical question: Explicitly state the funding question (continue/cease/change/reduce medication)
- Current medication profile: Complete list with doses, indications, start dates
- Functional status: Current functional capacity and recovery progress toward goals
- Medical input: What does the treating provider recommend and why
- Claimant concerns: Any side effects, adherence issues, or concerns the claimant has expressed
- Cost considerations: Current medication costs and projected ongoing costs
- Timeline context: Time post-injury and expected recovery timeline
Pharmacy review with complete information provides specific recommendations on evidence-based funding decisions.
Communicating funding decisions based on pharmacy review
When you make medication funding decisions based on pharmacy review, communicate them clearly:
Funding decision communication template
To: [Claimant and medical provider]
Date: [Date of decision]
Re: Medication funding decision regarding [medication name]
Decision: [Fund/cease/change/modify] [medication name] effective [date]
Clinical basis: "Specialist pharmacy review was conducted to assess the evidence for [medication]. The review concluded [key findings]. Based on these findings, we are [funding decision]."
Implementation: [How decision will be implemented, timeline for changes]
Ongoing support: [How claimant and provider will be supported through medication change if applicable]
Next review: [When next medication review will occur]
Managing funding decision disputes
Despite good documentation, funding decisions can be challenged by claimants or medical providers. Pharmacy review provides your foundation for defence:
Claimant disputes funding decision
Claimant complaint: "I need this medication and you're denying it to save money."
Response using pharmacy review: "We engaged independent clinical pharmacy review specifically to ensure your medication is appropriate and necessary. The review concluded that [specific finding]. Our funding decision is based on this clinical assessment, not cost consideration."
Medical provider disputes funding decision
Provider complaint: "I am the treating provider. I know best what this patient needs. Stop second-guessing my treatment."
Response using pharmacy review: "We value your clinical input and have sought specialist medication review to complement your treatment. The review identified [specific findings]. We would welcome discussion about how to address this while continuing to support your treatment goals."
Appeals and reassessment
When funding decisions are appealed, offer to conduct additional pharmacy review or reassessment if circumstances have changed. This demonstrates fairness and openness to reconsideration while maintaining consistent decision-making standards.
Building a framework for evidence-based medication funding
Over time, develop internal guidelines for medication funding based on pharmacy review findings and outcomes. These guidelines provide consistency to your decisions and make it easier to explain your approach to claimants, medical providers, and stakeholders:
- Framework for funding pain medications across injury phases
- Guidelines for antidepressant duration and deprescribing
- Benzodiazepine funding restricted to acute phase with reduction plans
- High-cost or high-risk medications requiring specialist review before funding
- Expected medication durations for common injury-related conditions
- Process for appealing or reconsidering funding decisions
The strategic value of evidence-based funding decisions
Making medication funding decisions based on specialist pharmacy review offers multiple strategic benefits:
- Defensibility: Decisions rest on clinical evidence, not cost cutting
- Consistency: Similar cases receive similar treatment
- Claimant outcomes: Evidence-based decisions improve functional recovery
- Dispute reduction: Clear rationale reduces challenges and appeals
- Cost control: Inappropriate medications are identified and managed
- Provider relationships: Collaborative approach maintains good medical relationships
Integrating pharmacy review into your funding process
Make medication funding decisions more effectively by systematically incorporating pharmacy review:
- Establish trigger points for pharmacy review: complex regimens, cost escalation, treatment disputes, deprescribing decisions
- Build pharmacy review cost into your case management budget
- Develop standard funding frameworks based on pharmacy review findings
- Train your claims team on how to use pharmacy review in funding decisions
- Document pharmacy review findings in your claims file for consistency and transparency
- Use outcomes data to refine your funding frameworks over time
Ready to make more confident medication funding decisions?
IMM's medication review service provides the clinical evidence you need to support funding decisions. Request specialist pharmacy assessment to guide medication funding in your complex claims.
Request a Medication Review
